Organon & Co. (OGN) vs Sanofi (SNY)
Organon & Co. and Sanofi are both Drug Manufacturers General companies. Sanofi is the larger, with a market value of $97.4B against $3.6B — 27.1× the size. Organon & Co. trades at the lower P/E: 17.4× against 21.5×. Sanofi grew revenue faster over the last twelve months: 21.3% against −2.45%. Sanofi has the higher net margin (8.22% vs 3.41%) and the higher return on invested capital (6.58% vs 6.11%). Both pay a dividend; Organon & Co. yields more (6.88% vs 4.40%). Across the 23 metrics below, Sanofi leads on 15 and Organon & Co. on 8.
Valuation
Profitability
| Metric | OGN | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 52.68% | 72.78% | 72.77% |
| Operating margin | 13.45% | 18.24% | 18.90% |
| Net margin | 3.41% | 8.22% | 8.27% |
| Free cash flow margin | 7.57% | 25.53% | 17.25% |
| Return on equity | 24.04% | 5.87% | 6.97% |
| Return on assets | 1.57% | 3.21% | 2.76% |
| Return on invested capital | 6.11% | 6.58% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack